Constellation Pharmaceuticals (CNST) Posts Earnings Results

Constellation Pharmaceuticals (NASDAQ:CNST) announced its earnings results on Thursday. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.14), Fidelity Earnings reports.

Shares of Constellation Pharmaceuticals stock traded down $0.23 on Friday, reaching $5.86. 6,229 shares of the stock were exchanged, compared to its average volume of 19,381. Constellation Pharmaceuticals has a one year low of $5.57 and a one year high of $12.21.

CNST has been the topic of a number of analyst reports. Cann initiated coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “outperform” rating and a $21.00 target price on the stock. Oppenheimer initiated coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “outperform” rating and a $21.00 target price on the stock. Zacks Investment Research upgraded shares of Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research report on Monday, October 15th. JPMorgan Chase & Co. initiated coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “overweight” rating and a $17.00 target price on the stock. Finally, BMO Capital Markets initiated coverage on shares of Constellation Pharmaceuticals in a research report on Monday, August 13th. They set an “outperform” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $17.15.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/11/10/constellation-pharmaceuticals-cnst-posts-earnings-results.html.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Featured Story: What is Compound Annual Growth Rate (CAGR)?

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply